Isabella Ciccone, Associate Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
Assessing Clinical Relevancy of Visual Biomarkers in Alzheimer Disease: Alfredo A. Sadun, MD, PhD
April 22nd 2025The chief of ophthalmology at the Doheny Eye Institute discussed decades of research uncovering how Alzheimer can impact visual function and how retinal imaging may advance diagnosis. [WATCH TIME: 13 minutes]
Real-World Data Show Similar Comorbidity Rates With and Without Sodium Oxybate Treatment
April 21st 2025Data suggest no significant differences in comorbidity rates in a newly published study, highlighting dosing challenges and treatment patterns in patients receiving immediate-release sodium oxybate.
Evaluating Safety and Early Outcomes of Lecanemab Treatment for Alzheimer Disease: Philip Kuball, MD
April 18th 2025The resident in the Department of Neurology at NYU Langone Health discussed the preliminary findings of a 9-month study on lecanemab recently presented at the 2025 AAN Annual Meeting. [WATCH TIME: 2 minutes]
Celebrating Innovation in MS Research With the John Dystel Prize: Bruce Bebo, PhD
April 17th 2025The executive vice president of research at the National MS Society talked about how the award continues to honor transformative multiple sclerosis research and inspire the next generation of investigators. [WATCH TIME: 5 minutes]
Expanding Access to Whole Genome Sequencing in Parkinson Research: James Beck, PhD
April 17th 2025The chief scientific officer of the Parkinson’s Foundation discussed the foundation’s efforts to integrate whole genome sequencing into PD GENEration and expand access across diverse global populations. [WATCH TIME: 4 minutes]
Large Danish Cohort Study Reveals No Significant Association Between HLA Alleles and Migraine
April 16th 2025Although the study reported no evidence linking human leukocyte antigen alleles to migraine, the findings were not replicated, suggesting the HLA system may not be involved in migraine susceptibility.
Improving Timely ALS Diagnosis With the thinkALS Toolkit: Melody Schaeffer, PhD, MPH
April 14th 2025The senior director of mission programs at The ALS Association discussed how the thinkALS Toolkit can aid general neurologists in identifying and referring suspected cases more efficiently. [WATCH TIME: 5 minutes]
Building Community and Education Through the AMDAPP CME Conference: Kinsey McCartney, PA-C
April 13th 2025The physician assistant at UCSF Movement Disorder and Neuromodulation Center reflected on the value of AMDAPP in fostering professional connection, education, and patient-centered care among movement disorder APPs. [WATCH TIME: 3 minutes]
Exploring Noninvasive Brain Stimulation for Neurorehabilitation: Roy H. Hamilton, MD, MS, FAAN
April 10th 2025The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed the current research landscape, clinical challenges, and future directions for noninvasive neuromodulation techniques in neurorehabilitation. [WATCH TIME: 4 minutes]
The Key Role of Early and Balanced Blood Pressure Control in ICH Management: Kara R. Melmed, MD
April 9th 2025The clinical associate professor of neurology and neurosurgery at NYU Langone Health emphasized the importance of rapid, targeted blood pressure reduction and bundled care to improve outcomes in patients with intracerebral hemorrhage. [WATCH TIME: 4 minutes]
Phase 3 INFRONT-3 Study Details Baseline Characteristics of Participants With FTD-GRN
April 8th 2025A phase 3 trial investigating latozinemab, a monoclonal antibody therapy for frontotemporal dementia because of GRN mutations, reported baseline participant characteristics to better characterize this patient population.
CGRP Therapies as Potential First-Line Migraine Preventive Treatment: Andrew Charles, MD
April 7th 2025The director of the UCLA Goldberg Migraine Program discussed the advantages, evidence base, and evolving payor support for CGRP-targeting therapies as potentially a first-line option in migraine prevention. [WATCH TIME: 5 minutes]